Dose-Dependent Efficacy Results: As of the latest data cut, muzastotug achieved a 31% (8/26) confirmed overall response rate (ORR) in the combined 20 mg/kg dose cohorts, showing a clear improvement over the 13% ORR (5/39) in the combined 10 mg/kg dose cohorts Extended Durability: Median duration of response (mDOR) was not yet reached in the 20 mg/kg cohorts, with responses ongoing beyond 9 months; confirmed mDOR of 6.2 months in the 10 mg/kg cohorts Meaningful Progression-Free Survival (PFS): Median PFS was 6.7 months in the combined 20 mg/kg cohorts, outperforming the 4.8 months observed in the combined 10 mg/kg cohorts Favorable Overall Survival Results: In the 10 mg/kg cohorts (n=41; median follow-up, 23.8 months), median overall survival was 19.8 months, with 48% of patients alive at two years, showing the long-tail survival typical...

TORONTO, April 02, 2026 (GLOBE NEWSWIRE) — Hudbay Minerals Inc. (“Hudbay” or the “Company”) (TSX, NYSE: HBM) today announced that it has repaid in full all of its outstanding 4.50% senior unsecured notes due 2026 (the “2026 Notes”), which were originally issued in an aggregate principal amount of $600 million. All amounts are in U.S. dollars, unless otherwise noted. Hudbay repaid the outstanding aggregate principal amount of $472.5 million of 2026 Notes on maturity on April 1, 2026 using a combination of available cash on hand and a $272 million draw on its low-cost revolving credit facilities. The repayment of the 2026 Notes using available liquidity is consistent with Hudbay’s prudent balance sheet management and focus on cost of capital and provides the Company with improved financial flexibility in advance of a Copper World...

Topline safety and pharmacokinetic data expected in Q4 2026; an independent Data Monitoring Committee is overseeing the study SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, has treated the first patient in its Part C expansion study of the CBeyond Phase 2a trial to characterize safety and pharmacokinetics (PK) at exposures designed to challenge the peripheral restriction of nimacimab through intravenous (IV) administration over 16 weeks of treatment. These doses will set the benchmark for the safety profile of nimacimab and support higher dosing in combination with incretin therapies. The expansion study comprises two cohorts of nimacimab monotherapy (400...

SINGAPORE, April 02, 2026 (GLOBE NEWSWIRE) — Aurora Mobile Limited (NASDAQ: JG) (“Aurora Mobile” or the “Company”), a leading provider of customer engagement and marketing technology services, is pleased to announce that its Japanese subsidiary, Aurora Mobile Japan K.K., successfully participated as a sponsor and keynote speaker at the “Tourism × Web3 Summit 2026.” The event served as a premier stage for the Company to demonstrate how its AI-driven capabilities are revolutionizing the tourism and Web3 sectors. Keynote Highlights: Redefining Engagement with an AI-First ApproachAkio Mitobe, CTO of Aurora Mobile Japan K.K., delivered a special pitch on the transformative impact of EngageLab, the Company’s AI-first customer engagement platform. He introduced a “Full-Journey AI Engagement Ecosystem” that seamlessly...

New Lawson Analog Target Identified Near Original Discovery on Genesis TrendBracken Well at Grasslands Project, 325 km southwest of Lawson Discovery, is successfully cased after being drilled to a total depth of 2,600 meters  Mixed gas interval with Helium and Natural Hydrogen encountered in Upper Devonian at Bracken, followed by two Natural Hydrogen-dominant zones in basal Deadwood and Basement Complex; service rig operations for well completion and testing phase to begin after spring breakup Lawson “look-a-like” target identified just 12 km southwest of original Lawson Discovery, based on further review of legacy 2D seismic data High quality data set delivered from a 3D Seismic Survey completed on Genesis Trend covering 47 sq. km at the Lawson Natural Hydrogen Discovery and a broad area surrounding the Lawson Well – initial interpretations...

NEW YORK, April 2, 2026—Wix.com Ltd. (Nasdaq: WIX) (“Wix” or the “Company”) today announced the preliminary results of its “modified Dutch Auction” tender offer, which expired at one (1) minute after 11:59 P.M., New York City time, on April 1, 2026.  Based on the preliminary count by Equiniti Trust Company, LLC, the depositary for the tender offer (the “Depositary”), a total of 18,718,009 of Wix’s ordinary shares, par value NIS 0.01 per share (each, a “Share,” and collectively, the “Shares”), were properly tendered and not properly withdrawn at or below the purchase price of $92.00 per share. In accordance with the terms and conditions of the tender offer, and based on the preliminary count by the Depositary, Wix expects to accept for payment a total of 18,718,009 Shares, representing all Shares that were properly tendered and not properly...

All amounts are in United States dollars, unless otherwise stated. TORONTO, April 02, 2026 (GLOBE NEWSWIRE) —  Alamos Gold Inc. (TSX:AGI; NYSE:AGI) (“Alamos” or the “Company”) plans to release its first quarter 2026 financial results after market close on Wednesday, April 29, 2026. Senior management will host a conference call on Thursday, April 30, 2026 at 11:00 am ET to discuss the results. The Company will hold its 2026 Annual General Meeting of Shareholders (the “Annual Meeting”) on Thursday, May 28, 2026. Notice of First Quarter 2026 Results and Conference Call Participants may join the conference call via webcast or through the following dial-in numbers: Via Webcast: To view the live webcast, please register at www.alamosgold.com, or through the following link view webcast. Via Phone:         Toronto and International: (647)...